查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1371962

全球抗生素抗药性市场，到 2030 年的预测：按疾病、病原体、药物类别、作用方式、最终用户和地区进行的全球分析

Antibiotic Resistance Market Forecasts to 2030 - Global Analysis By Disease, Pathogen, Drug Class, Mechanism of Action, End User and By Geography.
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球抗生素抗药性市场规模为 87.5 亿美元，预计预测期内年复合成长率为 7.7%，到 2030 年将达到 147.1 亿美元。

常用于治疗各种感染疾病的药物称为抗生素。当细菌经历基因变化或突变，使它们在接触抗生素时能够生存和繁殖，从而使药物效果降低或完全消除时，就会出现抗生素抗药性。因此，这些抗药性细菌引起的感染疾病可能难以治疗、延长病情、增加治疗成本并增加死亡率。

据CDC称，美国抗生素抗药性感染疾病的发生率超过280万人，该疾病年度给该国带来的负担估计在210亿美元至340亿美元之间。在全球范围内，MRSA 造成了巨大的成本负担，因为已开发国家的抗药性平均为 25.0%，开发中国家约为​​ 40%。

抗生素抗药性感染疾病的患病不断增加

抗生素抗药性感染疾病的增加是抗生素抗药性市场的关键促进因素。抗生素的过度使用和滥用导致抗药性细菌的出现，使得传统抗生素的效果降低。抗药性细菌的增加对公众健康构成严重威胁，导致长期患病、死亡率增加和医疗费用增加。由抗生素抗药性细菌引起的感染疾病通常需要使用较昂贵且可能效果较差的二线治疗。因此，对创新抗生素和替代疗法来对抗这些抗药性病原体的需求不断增长。开发新型有效抗生素的需求正在推动製药和医疗保健领域的研发工作、吸引投资并促进合作研究。这些要素正在要素市场成长。

严格的法规标准

抗生素抗药性市场面临严格的法规要求，并对药物开发和市场开拓构成重大挑战。法规机构需要广泛的临床试验和完整的安全性和有效性文件，以确保新抗生素的有效性。满足这些要求需要投入大量时间和资源，通常会导致开发时间更长和成本更高。这些因素都阻碍了市场需求。

新型抗生素的开发

新抗生素的开发代表了抗生素抗药性市场的重大商机。抗生素抗药性细菌的增加增加了对能够有效对抗这些顽强病原体的创新药物的需求。投资新型抗生素的开发不仅是迫切的医疗需求，也是一个充满希望的商机。此外，考虑到有效抗生素的潜在市场需求和减轻抗生素抗药性的社会影响，需要公私伙伴关係和合作来推进抗生素研究，促进创新和开发新抗生素，我们正在创造良好的环境以促进发展和商业化

抗生素的过度使用和滥用

抗生素的过度使用和滥用对抗生素抗药性市场构成了重大威胁。抗生素的过度处方和不当使用通常是由患者需求、缺乏适当的诊断工具或医疗保健专业人员的处方习惯引起的，会导致抗生素抗药性菌株的产生。当不必要或不当地使用抗生素时，细菌更有可能产生抗药性，使其不再有效。这些要素导致市场成长放缓。

COVID-19 的影响

在 COVID-19 患者中，在大流行早期，用于治疗继发性细菌感染的抗生素的使用和需求增加。增加使用可能会导致抗生素抗药性。此外，公众、医疗保健专业人员和政治家的认识不断提高，人们更了解了与抗生素抗药性相关的风险以及适当和负责任地使用抗生素的必要性。这次大流行提醒人们抗生素管理计划的价值，这些计划鼓励负责任地使用抗生素并帮助对抗抗生素抗药性疾病。医疗保健系统已优先进行此类配合措施，以确保按需要的时间和数量给药足够的抗生素，以阻止抗药性疾病的传播。整体而言，疫情对全球市场需求产生了正面影响。

四环素抗生素市场预计将在预测期内成为最大的市场

四环素类药物预计将占据最大份额。四环素类抗生素是四环素类抗生素的一种；四环素类抗生素是四环素类抗生素的一种。四环素抗生素是一类用于治疗多种细菌感染疾病的抗生素，由于抗生素抗药性菌株的出现而面临挑战。此外，医疗保健组织和法规机构正在促进负责任的抗生素使用并实施严格的指导方针以遏制抗药性细菌的传播。在四环素领域，正在进行的研究和合作为对抗抗生素抗药性和确保感染疾病的有效治疗方法提供了一个有希望的途径。

医院和诊所领域预计在预测期内年复合成长率最高

预计医院和诊所部门在预测期内将出现良好的成长。抗生素抗药性市场的医院和诊所部分在管理和应对抗生素抗药性感染疾病带来的挑战方面发挥着重要作用。医疗机构处于诊断和治疗患者的第一线，因此面临抗生素抗药性的直接影响。这部分包括医院、诊所和其他提供医疗服务的医疗机构。这些环境中的医疗保健专业人员积极参与实施抗菌药物管理计划、促进感染预防和控制措施以及优化抗生素的使用。此外，医院和诊所还透过监测流行病和抗生素抗药性模式，并与研究人员和法规机构合作制定应对这项全球健康威胁的策略，为监测工作做出贡献。

比最大的地区

由于该地区感染疾病高发生率而广泛使用抗生素，亚太地区在估计期间占据了最大的市场占有率。亚太地区是全球最大的抗生素使用地区，有可能出现抗生素抗药性疾病。抗生素抗药性细菌的出现和传播是由于不当使用（包括过度使用和滥用抗生素）造成的。此外，亚太地区人口稠密，抗生素抗药性疾病负担负担，使其成为抗药性细菌扩散的中心。人们对抗生素抗药性的认识不断提高，以及对有效干预措施的需求正在推动该地区解决这一问题的配合措施。

复合年复合成长率最高的地区

预计北美在预测期内将实现盈利成长。北美地区抗生素抗药性患病很高，据报导抗生素抗药性感染疾病负担很大。这是由于医疗机构和社区过度使用和滥用抗生素等要素造成的。该地区也表现出强大的研发活动，重点是开发新的抗生素和替代治疗方法。此外，北美的政府配合措施和官民合作关係关係透过实施抗生素管理计画和提高对适当使用抗生素的认识，在解决抗生素抗药性方面发挥重要作用。

免费客製化服务：

订阅此报告的客户可以利用以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究来源
    • 主要研究来源
    • 二次研究来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球抗生素抗药性市场：依疾病分类

  • 艰难梭菌感染疾病
  • 院内细菌性肺炎
  • 复杂性腹腔内感染疾病
  • 社区型细菌性肺炎
  • 急性细菌性皮肤和皮肤结构感染疾病
  • 血流感染疾病
  • 复杂性尿道感染

第6章全球抗生素抗药性市场：依病原体分类

  • 鲍马尼
  • 铜绿假单胞菌
  • 屎肠球菌
  • 流感嗜血桿菌
  • 肺炎克雷伯菌
  • 大肠桿菌
  • 肺炎链球菌
  • 艰难梭菌
  • 金黄色葡萄球菌
  • 鲍氏不动桿菌

第7章全球抗生素抗药性市场：依药物类别

  • 四环素类
  • 头孢菌素类
  • 噁唑烷酮
  • 联合治疗
  • 胜肽
  • 其他药物类别

第8章全球抗生素抗药性市场：按作用机制

  • 细胞壁合成抑制剂
  • DNA合成抑制剂
  • 蛋白质合成抑制剂
  • RNA合成抑制剂
  • 其他作用机制

第9章全球抗生素抗药性市场：依最终用户分类

  • 医院/诊所
  • 居家护理
  • 研究机构
  • 其他最终用户

第10章全球抗生素抗药性市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第11章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第12章公司简介

  • Basilea Pharmaceutica Ltd.
  • Tetraphase Pharmaceuticals, Inc.
  • Entasis therapeutics
  • Theravance Biopharma
  • Paratek Pharmaceuticals, Inc.
  • Seres Therapeutics
  • Merck & Co. Inc.
  • Achaogen Inc.
  • Melinta Therapeutics
  • AbbVie, Inc.
  • Johnson & Johnson
  • Pfizer Inc.
  • Cipla Ltd.
  • Bayer AG
  • AstraZeneca plc
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Roche Holding AG
  • Cubist Pharmaceuticals, Inc.
  • Mylan NV
Product Code: SMRC24019

According to Stratistics MRC, the Global Antibiotic Resistance Market is accounted for $8.75 billion in 2023 and is expected to reach $14.71 billion by 2030 growing at a CAGR of 7.7% during the forecast period. The drugs that are frequently used to treat a variety of infections are referred to as antibiotics. When bacteria endure genetic changes or mutations that allow them to live and grow even when exposed to antibiotics, antibiotic resistance develops, diminishing or completely removing the effectiveness of the drugs. As a result, infections brought on by these resistant bacteria become more challenging to treat, which causes illnesses to last longer, cost more money to treat, and may raise fatality rates.

According to the CDC, the incidence of antibiotic-resistant infections is more than 2.8 million in the U.S. The annual burden of the disease in the country is estimated between USD 21.0 billion to USD 34.0 billion. Globally, MRSA imposes a significant cost burden due to a high resistance rate of an average of 25.0% in developed countries and around 40% in developing regions.

Market Dynamics:

Driver:

Increasing Prevalence of Antibiotic-Resistant Infections

The increasing prevalence of antibiotic-resistant infections is a critical driver of the antibiotic resistance market. Overuse and misuse of antibiotics have led to the emergence of resistant strains of bacteria, rendering conventional antibiotics less effective. This escalating resistance poses a serious threat to public health, resulting in prolonged illnesses, increased mortality rates, and higher healthcare costs. Infections caused by antibiotic-resistant bacteria often necessitate the use of more expensive and potentially less effective second-line treatments. Consequently, there is a growing demand for innovative antibiotics and alternative therapies to combat these resistant pathogens. The need to develop new and effective antibiotics is fueling research and development efforts, attracting investments, and driving collaborations within the pharmaceutical and healthcare sectors. These factors are responsible for market growth.

Restraint:

Stringent regulatory standards

The antibiotic resistance market faces stringent regulatory requirements that can pose significant challenges for drug development and market entry. Regulatory agencies demand extensive clinical trials and thorough documentation of safety and efficacy to ensure the effectiveness of new antibiotics. Meeting these requirements necessitates substantial investments of time and resources, often resulting in prolonged development timelines and increased costs. These elements are hampering market demand.

Opportunity:

Development of novel antibiotics

The development of novel antibiotics presents a significant opportunity within the antibiotic resistance market. With the rise of antibiotic-resistant bacterial strains, there is an emerging need for innovative drugs that can effectively combat these resilient pathogens. Investing in the development of novel antibiotics is not only a healthcare imperative but also a promising business opportunity. Additionally, public-private partnerships and collaborations are fostering a good environment for advancing antibiotic research, encouraging innovation, and expediting the development and commercialization of new antibiotics, driven by the potential market demand for effective antibiotics and the societal impact of mitigating antibiotic resistance.

Threat:

Overuse and Misuse of Antibiotics

Overuse and misuse of antibiotics constitute a significant threat to the antibiotic resistance market. Over-prescription and inappropriate use of antibiotics, often driven by patient demand, a lack of proper diagnostic tools, or medical practitioners' prescribing habits, contribute to the development of antibiotic-resistant strains. When antibiotics are used unnecessarily or incorrectly, bacteria have a higher chance of developing resistance, rendering these drugs ineffective. These factors are responsible for decreasing market growth.

COVID-19 Impact

Antibiotic use and demand increased among COVID-19 patients early in the pandemic to treat secondary bacterial infections. Antibiotic resistance may occur as a result of the increased use. Additionally, there is a better understanding of the risks associated with antibiotic resistance and the necessity for appropriate and responsible antibiotic usage as a result of the increasing awareness among the general public, healthcare professionals, and politicians. The pandemic served as a reminder of the value of antibiotic management programmes, which encourage the responsible use of antibiotics and aid in the fight against antibiotic-resistant illnesses. Healthcare systems gave priority to such initiatives to make sure that antibiotics are only given when necessary and in sufficient quantities to stop the spread of illnesses that are resistant to therapy. Overall, the pandemic had a positive impact on global market demand.

The Tetracyclines segment is expected to be the largest during the forecast period

The Tetracyclines segment is estimated to hold the largest share. This has fuelled the demand for alternative treatment options and the development of novel antibiotics. Tetracyclines, a class of antibiotics used to treat a wide range of bacterial infections, have faced challenges due to the emergence of antibiotic-resistant strains. Additionally, healthcare organisations and regulatory bodies are promoting responsible antibiotic use and implementing stringent guidelines to curb the spread of resistance. While the tetracycline's segment has ongoing research and collaborative efforts hold promise for addressing antibiotic resistance and ensuring effective treatment options for infectious diseases.

The Hospitals & Clinics segment is expected to have the highest CAGR during the forecast period

The Hospitals & Clinics segment is anticipated to have lucrative growth during the forecast period. The hospitals and clinics segment of the antibiotic resistance market plays a crucial role in managing and combating the challenges posed by antibiotic-resistant infections. As healthcare facilities are at the forefront of diagnosing and treating patients, they face the direct impact of antibiotic resistance. This segment encompasses hospitals, clinics, and other healthcare institutions that provide medical services. Healthcare professionals in these settings are actively involved in implementing antimicrobial stewardship programmes, promoting infection prevention and control measures, and optimising the use of antibiotics. Furthermore, hospitals and clinics contribute to surveillance efforts by monitoring the prevalence and patterns of antibiotic resistance and collaborating with researchers and regulatory bodies to develop strategies for combating this global health threat.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to the high prevalence of infectious diseases in the area, extensive antibiotic use has resulted. It represents the greatest user of antibiotics in the world, which raises the possibility of developing diseases with antibiotic resistance. Antibiotic-resistant bacteria have emerged and spread as a result of improper usage of antibiotics, including overuse and misuse. Additionally, the Asia-Pacific area is a hub for the propagation of resistance due to its dense population and high load of diseases that are antibiotic-resistant. The growing awareness about antibiotic resistance and the need for effective interventions are driving efforts to combat the issue in the region.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. North America region has a high prevalence of antibiotic resistance, with a significant burden of antibiotic-resistant infections reported. This is attributed to factors such as the overuse and misuse of antibiotics, both in healthcare settings and in the community. region also exhibits robust research and development activities focused on developing new antibiotics and alternative treatment options. Additionally, government initiatives and public-private partnerships in North America have played a crucial role in addressing antibiotic resistance through the implementation of antibiotic stewardship programmes and raising awareness about appropriate antibiotic use.

Key players in the market

Some of the key players in the Antibiotic Resistance Market include: Basilea Pharmaceutica Ltd., Tetraphase Pharmaceuticals, Inc., Entasis therapeutics, Theravance Biopharma, Paratek Pharmaceuticals, Inc., Seres Therapeutics, Merck & Co. Inc., Achaogen Inc., Melinta Therapeutics, AbbVie, Inc., Johnson & Johnson, Pfizer Inc., Cipla Ltd., Bayer AG, AstraZeneca plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Roche Holding AG, Cubist Pharmaceuticals, Inc. and Mylan N.V.

Key Developments:

In June 2023, BSI, the business improvement and Standards Company, launched a new global Minimized Risk of Antimicrobial Resistance (AMR) certification designed to promote and attest to the responsible manufacturing of antibiotics in the global supply chain.

In November 2022, Quadripartite launches a new platform to tackle antimicrobial resistance threat to human and animal health and ecosystems. The Antimicrobial Resistance Multi-Stakeholder Partnership Platform was launched today to ensure the growing threats and impacts of antimicrobial resistance are addressed globally.

In November 2022, Apollo announced the launch of an Antimicrobial Stewardship Programme (Apollo ASP). The programme will sensitize care providers on Antimicrobial Resistance (AMR), an issue leading to a public health problem.

In April 2022, Johnson & Johnson announced the opening of the J&J Satellite Center for Global Health Discovery (Satellite Center) at the University of Cape Town's Holistic Drug Discovery and Development (H3D).

Diseases Covered:

  • Clostridium difficile infections
  • Hospital-acquired bacterial pneumonia
  • Complicated intra-abdominal infections
  • Community-acquired bacterial pneumonia
  • Acute bacterial skin and skin-structure infection
  • Bloodstream infection
  • Complicated urinary tract infections

Pathogens Covered:

  • Baumannii
  • Pseudomonas aeruginosa
  • Enterococcus faecium
  • Hemophilus Influenzae
  • K. Pneumoniae
  • E. Coli
  • Streptococcus pneumoniae
  • Clostridium difficile
  • Staphylococcus Aureus
  • Acinetobacter

Drug Classes Covered:

  • Tetracyclines
  • Cephalosporins
  • Oxazolidinones
  • Combination therpaies
  • Lipoglycopeptides
  • Other Drug Classes

Mechanism of Actions Covered:

  • Cell Wall Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • RNA synthesis inhibitors
  • Other Mechanism of Actions

End Users Covered:

  • Hospitals & Clinics
  • Homecare
  • Research Organizations
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Antibiotic Resistance Market, By Disease

  • 5.1 Introduction
  • 5.2 Clostridium difficile infections
  • 5.3 Hospital-acquired bacterial pneumonia
  • 5.4 Complicated intra-abdominal infections
  • 5.5 Community-acquired bacterial pneumonia
  • 5.6 Acute bacterial skin and skin-structure infection
  • 5.7 Bloodstream infection
  • 5.8 Complicated urinary tract infections

6 Global Antibiotic Resistance Market, By Pathogen

  • 6.1 Introduction
  • 6.2 Baumannii
  • 6.3 Pseudomonas aeruginosa
  • 6.4 Enterococcus faecium
  • 6.5 Hemophilus Influenzae
  • 6.6 K. Pneumoniae
  • 6.8 E. Coli
  • 6.9 Streptococcus pneumoniae
  • 6.10 Clostridium difficile
  • 6.11 Staphylococcus Aureus
  • 6.12 Acinetobacter

7 Global Antibiotic Resistance Market, By Drug Class

  • 7.1 Introduction
  • 7.2 Tetracyclines
  • 7.3 Cephalosporins
  • 7.4 Oxazolidinones
  • 7.5 Combination therpaies
  • 7.6 Lipoglycopeptides
  • 7.7 Other Drug Classes

8 Global Antibiotic Resistance Market, By Mechanism of Action

  • 8.1 Introduction
  • 8.2 Cell Wall Synthesis Inhibitors
  • 8.3 DNA Synthesis Inhibitors
  • 8.4 Protein Synthesis Inhibitors
  • 8.5 RNA synthesis inhibitors
  • 8.6 Other Mechanism of ActionS

9 Global Antibiotic Resistance Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Homecare
  • 9.4 Research Organizations
  • 9.5 Other End Users

10 Global Antibiotic Resistance Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Basilea Pharmaceutica Ltd.
  • 12.2 Tetraphase Pharmaceuticals, Inc.
  • 12.3 Entasis therapeutics
  • 12.4 Theravance Biopharma
  • 12.5 Paratek Pharmaceuticals, Inc.
  • 12.6 Seres Therapeutics
  • 12.7 Merck & Co. Inc.
  • 12.8 Achaogen Inc.
  • 12.9 Melinta Therapeutics
  • 12.10 AbbVie, Inc.
  • 12.11 Johnson & Johnson
  • 12.12 Pfizer Inc.
  • 12.13 Cipla Ltd.
  • 12.14 Bayer AG
  • 12.15 AstraZeneca plc
  • 12.16 Novartis AG
  • 12.17 Teva Pharmaceutical Industries Ltd.
  • 12.18 Roche Holding AG
  • 12.19 Cubist Pharmaceuticals, Inc.
  • 12.20 Mylan N.V.

List of Tables

  • Table 1 Global Antibiotic Resistance Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Antibiotic Resistance Market Outlook, By Disease (2021-2030) ($MN)
  • Table 3 Global Antibiotic Resistance Market Outlook, By Clostridium difficile infections (2021-2030) ($MN)
  • Table 4 Global Antibiotic Resistance Market Outlook, By Hospital-acquired bacterial pneumonia (2021-2030) ($MN)
  • Table 5 Global Antibiotic Resistance Market Outlook, By Complicated intra-abdominal infections (2021-2030) ($MN)
  • Table 6 Global Antibiotic Resistance Market Outlook, By Community-acquired bacterial pneumonia (2021-2030) ($MN)
  • Table 7 Global Antibiotic Resistance Market Outlook, By Acute bacterial skin and skin-structure infection (2021-2030) ($MN)
  • Table 8 Global Antibiotic Resistance Market Outlook, By Bloodstream infection (2021-2030) ($MN)
  • Table 9 Global Antibiotic Resistance Market Outlook, By Complicated urinary tract infections (2021-2030) ($MN)
  • Table 10 Global Antibiotic Resistance Market Outlook, By Pathogen (2021-2030) ($MN)
  • Table 11 Global Antibiotic Resistance Market Outlook, By Baumannii (2021-2030) ($MN)
  • Table 12 Global Antibiotic Resistance Market Outlook, By Pseudomonas aeruginosa (2021-2030) ($MN)
  • Table 13 Global Antibiotic Resistance Market Outlook, By Enterococcus faecium (2021-2030) ($MN)
  • Table 14 Global Antibiotic Resistance Market Outlook, By Hemophilus Influenzae (2021-2030) ($MN)
  • Table 15 Global Antibiotic Resistance Market Outlook, By K. Pneumoniae (2021-2030) ($MN)
  • Table 16 Global Antibiotic Resistance Market Outlook, By E. Coli (2021-2030) ($MN)
  • Table 17 Global Antibiotic Resistance Market Outlook, By Streptococcus pneumoniae (2021-2030) ($MN)
  • Table 18 Global Antibiotic Resistance Market Outlook, By Clostridium difficile (2021-2030) ($MN)
  • Table 19 Global Antibiotic Resistance Market Outlook, By Staphylococcus Aureus (2021-2030) ($MN)
  • Table 20 Global Antibiotic Resistance Market Outlook, By Acinetobacter (2021-2030) ($MN)
  • Table 21 Global Antibiotic Resistance Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 22 Global Antibiotic Resistance Market Outlook, By Tetracyclines (2021-2030) ($MN)
  • Table 23 Global Antibiotic Resistance Market Outlook, By Cephalosporins (2021-2030) ($MN)
  • Table 24 Global Antibiotic Resistance Market Outlook, By Oxazolidinones (2021-2030) ($MN)
  • Table 25 Global Antibiotic Resistance Market Outlook, By Combination therpaies (2021-2030) ($MN)
  • Table 26 Global Antibiotic Resistance Market Outlook, By Lipoglycopeptides (2021-2030) ($MN)
  • Table 27 Global Antibiotic Resistance Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 28 Global Antibiotic Resistance Market Outlook, By Mechanism of Action (2021-2030) ($MN)
  • Table 29 Global Antibiotic Resistance Market Outlook, By Cell Wall Synthesis Inhibitors (2021-2030) ($MN)
  • Table 30 Global Antibiotic Resistance Market Outlook, By DNA Synthesis Inhibitors (2021-2030) ($MN)
  • Table 31 Global Antibiotic Resistance Market Outlook, By Protein Synthesis Inhibitors (2021-2030) ($MN)
  • Table 32 Global Antibiotic Resistance Market Outlook, By RNA synthesis inhibitors (2021-2030) ($MN)
  • Table 33 Global Antibiotic Resistance Market Outlook, By Other Mechanism of ActionS (2021-2030) ($MN)
  • Table 34 Global Antibiotic Resistance Market Outlook, By End Users (2021-2030) ($MN)
  • Table 35 Global Antibiotic Resistance Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 36 Global Antibiotic Resistance Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 37 Global Antibiotic Resistance Market Outlook, By Research Organizations (2021-2030) ($MN)
  • Table 38 Global Antibiotic Resistance Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.